A2 Milk Ltd. reported a 44% [2] drop in reported net profit for the fiscal year ending June 2024.
The results highlight the volatility of the infant formula market, where high capital investments and supply-chain stability can outweigh steady sales growth.
Revenue for the period rose 12.4% to $1.97 billion [1], a figure that remained roughly in line with company forecasts. Despite the top-line growth, the company faced significant one-off expenses that eroded its reported earnings. The primary driver of the profit decline was a $282 million [1] acquisition cost for an infant formula facility located at Pōkeno.
Operational challenges also weighed on the company's performance. A supply-chain disruption occurred during the fourth quarter [1], which hampered the company's ability to meet demand. Additionally, the company experienced weaker sales of its infant formula product labeled for the China market [3].
There is a distinction between the company's reported and underlying earnings. While the reported net profit fell, the underlying net profit increased seven percent to $235.8 million [1]. This suggests that the core business operations remained profitable, but the final accounting was skewed by the facility purchase and temporary logistics failures.
The company's headquarters in New Zealand managed the fallout of the final-quarter supply issues [2]. These disruptions, combined with the strategic acquisition, created a gap between the company's revenue growth and its actual net take-home pay for the fiscal year.
“Reported net profit fell 44%”
The divergence between A2 Milk's rising revenue and falling reported profit indicates a transition phase. By investing heavily in its own manufacturing infrastructure via the Pōkeno facility, the company is attempting to reduce long-term reliance on third-party suppliers and stabilize its supply chain. However, the weakness in China-label sales suggests that the company must navigate a tightening competitive landscape in its most critical export market.
